Status:
COMPLETED
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
Lead Sponsor:
Center Eugene Marquis
Conditions:
Glioblastoma
Glioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients. Unfortunately some pati...
Detailed Description
The following leucocyte subsets will be analyzed in whole blood before treatment and before cycles 3, 5 and 7: * Classical, intermediate, nonclassical and Tie2 expressing monocytes. * Regulatory T ce...
Eligibility Criteria
Inclusion
- Patients with histologically proved recurrent glioblastoma or anaplasic glioma,
- Tumor recurrence documented by MRI at least 3 months after the end of radiotherapy or chemotherapy.
- Patients for whom a treatment by bevacizumab is proposed by a multidisciplinary team staff.
- Age ≥ 18.
- Signed informed consent.
- Affiliation to a social security coverage
Exclusion
- Known Hepatitis B or C or HIV.
- Inclusion in another clinical trial.
- Patient having received an anti-angiogenic therapy.
- Pregnant or breast-feeding woman.
- Person deprived of liberty or under guardianship or trusteeship or judicial protection
- Inability to give informed consent
- Person unable or unwilling to comply with the requirements of the protocol for geographical, social or psychological reasons.
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01836536
Start Date
September 1 2012
End Date
August 1 2015
Last Update
March 1 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Avicenne
Bobigny, France, 93009
2
Center Eugene Marquis
Rennes, France, 35042